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Abstract. Definition of the clinical target volume (CTV) is one of the weakest links
in the radiation therapy chain. In particular, inability to account for uncertainties is a
severe limitation in the traditional CTV delineation approach. Here, we introduce and
test a new concept for tumor target definition, the clinical target distribution (CTD).
The CTD is a continuous distribution of the probability of voxels to be tumorous.
We describe an approach to incorporate the CTD in treatment plan optimization
algorithms, and implement it in a commercial treatment planning system. We test
the approach in two synthetic and two clinical cases, a sarcoma and a glioblastoma
case. The CTD is straightforward to implement in treatment planning and comes with
several advantages. It allows one to find the most suitable tradeoff between target
coverage and sparing of surrounding healthy organs at the treatment planning stage,
without having to modify or redraw a CTV. Owing to the variable probabilities afforded
by the CTD, a more flexible and more clinically meaningful sparing of critical structure
becomes possible. Finally, the CTD is expected to reduce the inter-user variability of
defining the traditional CTV.
Keywords: clinical target volume, clinical target distribution, robust optimization,
multi-criteria optimization
1. Introduction
The definition of the clinical target volume (CTV) is becoming the weakest link of the
radiation therapy chain (Austin-Seymour et al., 1995, Weiss and Hess, 2003, Schlegel
et al., 2006, Njeh, 2008). The variability in defining the CTV, especially the inter-
observer variability, has been documented in numerous publications. A recent systematic
review reveals the vast body of literature on this topic published since the year 2000
alone (Vinod et al., 2016). The variability/uncertainty in defining the CTV can easily
reach one centimeter and more, and it is thus almost one order of magnitude bigger
than the millimeter uncertainties in delivering dose to the tumor.
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2Recent studies indicate a higher risk of treatment failures in some highly conformal
treatments, which could be attributed to inadequately defined CTVs (Engels et al.,
2009). CTV uncertainties could be particularly detrimental in proton or charged particle
therapy, with steeper dose gradients (Baumann et al., 2016) and without the potentially
forgiving “dose bath” of conventional radiotherapy.
There is also a more fundamental conceptual weakness in the current CTV
approach: By design, the CTV is a binary concept, which forces the contouring physician
to make a yes/no decision as to whether a certain area is tumor target or not. Given
the fundamental uncertainties associated with this process, forced binary decisions can
lead to some level of arbitrariness in the choice of the CTV, which may explain the
variability in defining the CTV.
There have been other attempts in previous years to deal with CTV uncertainties in
a more explicit way. Notably, 20 years ago Waschek et al. proposed a concept where the
physicians draw an inner CTV contour which definitely contains tumor, and an outer
CTV contour outside of which there is definitely no tumor. The vague region between
these contours was handled through Fuzzy Logic (Waschek et al., 1997). The concept
has not been put to practice. This may be in part due to the fact that Fuzzy Logic
has not lived up to its promise from the 1980s and 1990s. There have been very few
approaches to incorporate CTV delineation uncertainties in treatment plan optimization
(Balvert, 2017), and all of them are based on the standard binary CTV concept.
In this paper we put forward a continuous probabilistic concept of CTV, which we
call the clinical target distribution, CTD. Like the physical dose distribution, the CTD
is a three-dimensional discrete distribution. The CTD at a voxel i is the probability pi
that the voxel contains tumor cells. It generally drops from 100% near the gross tumor
volume (GTV) to 0% further away from the GTV.
The CTD can be determined using pathological examinations of microscopic disease
extension beyond the GTV (van Loon et al., 2012, Siedschlag et al., 2011, Akiyama et al.,
2018). It can also be guided by CTV contouring studies involving many physicians
(by measuring the overlap between them). It can further be informed by anatomic
compartments derived from diagnostic images, and their known characteristics with
respect to tumor spread.
The main focus of this paper is not how to determine the CTD. The purpose is
rather to
(i) put forward the CTD concept to account for the variable probability of tumor
extent beyond the GTV,
(ii) include the CTD in treatment plan optimization, and
(iii) demonstrate that the CTD-optimized plans are in some sense superior to
conventional CTV-based plans.
32. Materials and Methods
2.1. Constructing the CTD
The probabilities needed for the CTD distribution can be derived in various ways, as
mentioned above, or they can be entered directly by the physician. A realistic scenario
is where the physician or a trained imaging algorithm is able to draw and label H shells,
from innermost (1) to outermost (H) with probabilities rh, where rh is the probability
that there is tumor outside shell h, thus r1 > r2 > . . . > rH . For clarity let us assume
the final shell H is drawn such that it is the shell with the smallest probability rH = 0%,
i.e. absolute certainty that there are no tumorous voxels outside shell H. An inner shell
with, say, rh = 40% means that of 100 patients, 40 would have tumor outside of that
shell.
Now let sh = 1 − rh be the probability that there is no tumor outside shell h.
Consider the layer of voxels from shell H − 1 to shell H. Let qH−1 be the probability
that a voxel in that layer is NOT tumorous, and let the number of voxels in that layer
be NH−1. Then, under the assumption that the voxels are independent, we have:
sH−1 = q
NH−1
H−1 (1)
thus qH−1 = (sH−1)
1
NH−1
In general we can solve for all of the q voxel level probabilities by using the
relationship:
sH−k = q
NH−k
H−k sH−k+1 (2)
which when inverted yields
qH−k =
(
sH−k
sH−k+1
) 1
NH−k
(3)
The voxel probabilities of being tumorous p are simply p = 1− q. If the voxels are not
independent, these equations have to be modified accordingly. However, the independent
voxel assumption appears to be reasonable in absence of further knowledge, and it is
the one commonly made in tumor control probability models.
Note that throughout this paper we consistently distinguish between shells and
layers. Shells are infinitely thin surfaces on both sides of layers of voxels. The h-th layer
of voxels is the region (volume) between shell h and shell h + 1. See the example in
figure 1(a). The third layer of voxels (yellow-tinted) is between the third shell r3 = 0.4
(yellow contour) and the fourth shell r4 = 0.2 (green contour).
2.2. Including probabilities in treatment plan optimization algorithms
The usual way to define the objectives in treatment plan optimization is through the
sum of dose-dependent terms (such as piecewise quadratic or piecewise linear terms)
f(di) in the different voxels:
F =
∑
i
f(di). (4)
4We generalize this objective function to the case with voxel probabilities pi < 1 by a
weighted sum approach:
F =
∑
i
pif(di). (5)
We will justify this approach below using tumor control probabilities. Note that the
only mathematical difference between the standard CTV and the new CTD methods is
the choice of probabilities pi. In the CTV method the pi equal 1 in the CTV and are 0
elsewhere, whereas in the CTD method the pi can be arbitrary numbers.
Our general strategy for comparing treatment plans using the new CTD approach
with the conventional CTV method is to use the same sets of constraints to keep the
critical structures within acceptable dose limits, and the GTV covered by the prescribed
dose. The only objective is to keep the dose in the CTD/CTV outside of the GTV as
close to the prescription dose as possible. As our voxel-wise objective functions f(di)
we use quadratic underdose penalties (deviations from the target prescription dose level
dref) of the form:
f(di) ∝
[
dref − di
]2
+
, (6)
where [x]+ stands for x if x > 0, and [x]+ = 0 otherwise.
2.2.1. Justification using tumor control probabilities Here we motivate our pragmatic
approach to include the CTD in treatment plan optimization algorithms (equation (5))
through tumor control probability (TCP) models. Let us consider this simple yet widely
used TCP model (Webb and Nahum, 1993, Jin et al., 2011):
TCP = e−n e
−αd
, (7)
where n is the number of tumor cells in the finite tumor volume, α is the sensitivity
parameter and d is the radiation dose. Note that we can add a quadratic (βd2) term
to the dose, to reflect the linear-quadratic dose effect, but we omit it here to keep the
equations simple. For example, with n = 107 and α = 0.35 Gy−1, we achieve a tumor
control level of TCP = 95% with a dose of d = 54.5 Gy.
Now let us further consider that it is not certain that this volume is actually
tumorous. Let the probability of being tumor be p, such that the probability of not
being tumor is 1− p. Clearly, if it is not tumor, the TCP equals 1. So then the tumor
control probability changes to:
TCP = (1− p) + p e−n e−αd , (8)
which is always larger then 1− p.
If the overall tumor consists of independent smaller tumor sub-volumes, or
ultimately of voxels, we have
TCP =
∏
i
TCPi =
∏
i
(
(1− pi) + pi e−ni e−αdi
)
. (9)
5Finally, if every TCPi is close to one, which it has to be in order to ensure a
reasonably large overall TCP, we can write TCPi = 1−i with i close to 0. This yields:
TCP =
∏
i
(1− i) (10)
= 1−
∑
i
i + products and higher-order terms of i (11)
≈ 1−
∑
i
i, (12)
because the products and higher-order terms are negligible for small i. So therefore:
TCP ≈ 1−
∑
i
(1− TCPi) (13)
= 1−
∑
i
pi
(
1− e−ni e−αdi
)
. (14)
Note that this is the sum of voxel-level dose dependent terms weighted by voxel
probabilities pi, just like equation (5). Equation (14) could be implemented directly
as an objective function in optimization algorithms. However, to be more consistent
with current clinical practice, we use the quadratic underdose from equation (6) rather
than the double exponential above.
2.3. Synthetic and clinical cases studied
2.3.1. Synthetic cases To evaluate the feasibility of the CTD approach we created
IMRT plans on synthetic CT images comprising a target, organ at risk (OAR), and
probability shells. Two types of geometry were considered, a quasi 2D cylindrical
phantom with isotropic shells and a 3D deformed sphere phantom with anisotropic
shells. The isotropic shell phantom was designed with the target as a centrally positioned
cylinder of radius 2 cm, with an OAR being a shifted parallel cylinder of radius 1.7 cm
immediately adjacent to the target. The length of both cylinders was 10 cm. Five
concentric shells including the surface of the target and separated by 0.9 cm represented
probability levels of r1 =0.8, r2 =0.6, r3 =0.4, r4 =0.2 and r5 =0 (see figure 1(a)).
The anisotropic shell phantom was designed as three enclosed 3D shapes. All three
shapes consisted of a hemisphere as one part; the second part was one half of an oblate
spheroid (inner), a hemisphere (central) and a half of a prolate spheroid (outer). The
probability levels of r1 =0.4, r2 =0.2 and r3 =0 were assigned to the inner, central, and
outer shapes, respectively (see figure 1(b)).
For the symmetric shell phantom, two plans were created, one optimizing the dose
coverage of the conventional CTV under the mean dose limiting OAR constraint and
another optimizing the coverage of the layers between the shells under the same OAR
constraint. For the anisotropic shell phantom, three plans were created, optimizing the
dose coverage of the space between shapes under the constraint limiting the integral dose
within the whole phantom; three different levels of the integral dose were considered.
6Figure 1. Two geometric phantoms. (a) Five concentric probability shells distributed
equidistantly around a cylindrical target (red) and intersecting OAR (blue). The
layer 3 is yellow-tinted in this example. The CTV is the green (r4 =0.2) shell. (b)
Three anisotropically distributed shells, see text for details. The probability of finding
tumorous areas outside of the yellow, green, and cyan shell is 40%, 20%, and 0%,
respectively.
2.3.2. Clinical cases To test how our new approach performs on clinical cases, we
created treatment plans for two patients previously treated at our institution, one for
a cervical spine (c-spine) chordoma and the other for glioblastoma. There exists a
considerable variation among radiation oncologists in defining extended microscopic
disease for these tumors. Therefore, we speculate that relaxing a “solid” target
delineation will help to define the volume requiring prescription dose more consistently
across treating physicians.
Five probability shells for the c-spine chordoma case were delineated under the
guidance of a radiation oncologist and are shown in figure 2(a). The first shell, closest to
the GTV, was identified as having probability r1=0.8, and the voxels in the layer between
the GTV and the first shell were weighted with pi=1, the same as the voxels within the
GTV (note, voxels given pi=1 are treated as hard constraints by the optimizer: we
enforce that they get the prescribed dose). The second shell of r2=0.6 encompassed soft
tissues and edges of the vertebral body; it did not cross the surface of the spinal cord
or the surface of the pharynx. The third shell with r3=0.4 covered the entire vertebral
body and edges of the transverse process; it still did not cross the surface of the spinal
cord but intersected the pharynx. The entire spinal cord was encompassed by the next
shell with r4=0.2, also enclosed the processes; this shell was identified as CTV for the
clinical treatment plan. Finally, the outermost shell with r5=0 was drawn as a 3 mm
expansion of the CTV. Two plans were created: one optimizing the dose coverage of
the CTV under the constraints limiting mean dose to the spinal cord and pharynx; and
another optimizing the coverage of the layers between shells under the same constraints.
For the glioblastoma case, the probability shells were drawn based on the physician-
defined GTV and CTV. The surface of the GTV was assigned the probability r1=0.8.
7Figure 2. Probability shells delineated on the CT scan of (a) a c-spine chordoma,
and (b) a glioblastoma patient. In (a), five shells and the GTV are shown. The red
and the orange shells do not encompass the pharynx (pink) or spinal cord (blue), the
next shell (yellow) crosses the pharynx and bends around the spinal cord, and the
one matching the CTV (green) and the outermost (cyan) encompass the spinal cord.
In (b), five shells are shown, the surface of the GTV (red), the next two (orange and
yellow) which divide the space between the GTV and CTV, the one matching the CTV
(green), and the outermost (cyan). The shells are intersecting the brainstem (blue)
and optic chiasm (pink).
The space between the GTV and CTV was divided into three layers by drawing two
shells with probability levels r2=0.6 and r3=0.4. The CTV was assigned the level
r4=0.2. The outermost shell with r5=0 was drawn as a 5 mm expansion of the CTV
(see figure 2(b)). Three plans based on probabilistic CTD were created, optimizing the
dose coverage of the space between shells under the constraint limiting the integral dose
within the brain; three different levels of the integral dose were considered. In addition,
the maximal dose constraints were used to limit the dose to the brainstem and optic
chiasm.
2.4. Implementation in a commercial treatment planning system
Intensity-modulated radiation therapy (IMRT) plans were generated in the RayStation
5.0 treatment planning system (RaySearch Laboratories, Stockholm, Sweden) using a
linear accelerator with 6 MV photons. The dose calculation was performed using the
Collapsed Cone algorithm. The optimization objective functions and constraints were
used as specified in Table 1.
For synthetic cases, all plans utilized 15 equally spaced beams. The beam set for
the c-spine case consisted of 9 coplanar beams. For the glioblastoma case, the beam
set consisted of 8 beams including 5 coplanar and 3 non coplanar ones. Treatment plan
optimization parameters for all cases are listed in Table 1. Optimization cost function
8Table 1. Plan optimization parameters
Structure Function Dose level, Gy Weight
Isotropic shell phantom
Target Min dose 60 Constraint
CTDa Max dose 66 Constraint
OAR Mean dose 30 Constraint
CTV Min dose 60 1
Layer 1 Min dose 60 0.58
Layer 2 Min dose 60 0.20
Layer 3 Min dose 60 0.09
Layer 4 Min dose 60 0.05
Anisotropic shell phantom
CTD Max dose 63 Constraint
Patientb - CTD Max dose 60 Constraint
Patient Mean dose 10, 5, 2.95 Constraint
Layer 0 (inside shell 1) Min dose 61 7.26
Layer 1 Min dose 61 1.66
Layer 2 Min dose 61 0.54
C-spine chordoma patient
GTV + Layer 0 Min dose 50.4 Constraint
CTD Max dose 54 Constraint
Patient - CTD Max dose 52 Constraint
Spinal cord Mean dose 42 Constraint
Pharynx Mean dose 40 Constraint
CTV Min dose 50.4 1
Layer 1 Min dose 50.4 4.89
Layer 2 Min dose 50.4 1.19
Layer 3 Min dose 50.4 0.47
Layer 4 Min dose 50.4 0.39
Glioblastoma patient
GTV Min dose 62 Constraint
CTD Max dose 64 Constraint
Patient - CTD Max dose 62 Constraint
Brainstem Max dose 60 Constraint
Optic chiasm Max dose 54 Constraint
Brain Mean dose 48, 37, 31 Constraint
CTV Min dose 62 1
Layer 1 Min dose 62 2.21
Layer 2 Min dose 62 1.78
Layer 3 Min dose 62 0.65
Layer 4 Min dose 62 0.32
athe outermost shell; bexternal contour of a phantom or a patient;
Min dose: f(di) =
∆vi
dref
[
dref − di
]2
+
, where di is the dose in voxel i, d
ref is the reference dose level, and
∆vi is the relative volume of voxel i.
9included physical dose objectives and constraints. The constraints were chosen to ensure
the prescription dose coverage of the GTV, homogeneity of the dose distribution, and to
limit the dose to either the OAR or to the space outside the target. The objectives were
chosen to optimize the dose coverage of either the CTV or the probability layers within
the CTD. The weight for the only objective function in the CTV-based plan was set to 1.
Optimization objectives for the CTD-based plan were introduced according to equation
(5), where the weights for voxel layers between probability shells were calculated as
probabilities to find tumor in a voxel belonging to that layer pi = 1− qi, with qi defined
by equation (3). For example, for the four layers of the isotropic phantom, from inner
to outer, the number of voxels Nh in each layer for a single slice is N1 = 118, N2 = 204,
N3 = 313, and N4 = 447. The s values are s1 = 0.2, s2 = 0.4, s3 = 0.6, s4 = 0.8, and
s5 = 1. Using equation (3), qH−k =
(
sH−k
sH−k+1
) 1
NH−k , we have for k = 1 (note that H = 5
in this example): qH−k = q4 = (s4/s5)1/n4 = (.8/1)1/447 = .9995. Other q values are
computed similarly yielding the q vector [0.994, 0.998, 0.999, 0.9995]. The probability
weights are p = 1 − q = [0.00585, 0.0020, 0.0009, 0.0005]. The values of pi for each
plan were rescaled to be consistent with RayStation’s internal hardcoded functions that
control plan complexity. These were found through trial and error using guidance from
RayStation’s solver messages, in particular the phrase “Optimal solution found”, which
indicates good scaling (private communication with RaySearch research staff). Thus,
for example, in Table 1 the p values from the above example are scaled by a factor of
100 to bring them to [0.58, 0.2, 0.09, 0.05]. In both the CTV and CTD-based plans
the functional form of the objective and sets of constraints were the same as listed in
the caption of Table 1.
3. Results
3.1. Synthetic cases
Figure 3 shows the results for the isotropic shell phantom. The plan that optimizes the
coverage of the conventional CTV (figure 3(a)) is compared with the plan that optimizes
the coverage of probabilistic CTD with four layers (figure 3(b)). Since the mean dose
to the OAR is the same for the two plans, the difference is in the dose coverage of
the extended target. As one can see, the dose within extended target is distributed
more uniformly in the case of CTD, with better coverage of the inner and outer layer.
The distribution of dose within OAR is also different, the dose is higher in the region
immediately next to the target in the shell-based plan. The DVHs for the inner- and
outer-most layers, and the OAR, calculated from the two plans, are shown in figure 3(c).
In figure 4, the three plans created for the anisotropic shell phantom are compared.
Dose coverage of the CTD with three shells was optimized using three different levels
of integral dose, defined as the mean dose within the whole phantom, as a constraint.
With the integral dose limited to 10 Gy, the prescription dose conforms to the outermost
shell of the CTD (figure 4(a)). As the constraint hardens, i.e. the limit for the integral
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Figure 3. IMRT plans for the geometric phantom with isotropic shells with optimized
dose coverage of (a) CTV (green shell), and (b) CTD with four probability layers. The
innermost, layer 1 (between the red and orange shells) and outermost, layer 4 (between
the green and cyan shells) are shown. The constraint limiting the mean dose to the
OAR (blue structure) was used for both plans. (c) DVHs for layer 1 (orange lines),
layer 4 (cyan lines), and OAR (blue lines) calculated from the CTV plan (solid lines)
and from the CTD plan (dashed lines).
dose decreases to 5 Gy, the dose conforms to the middle shell (figure 4(b)); and when
the limit is equal to 2.95 Gy, only the layer within the innermost shell is covered with
the prescription dose (figure 4(c)). The DVHs for the outermost layer, calculated from
the three plans, are shown in figure 4(d).
3.2. Clinical cases
Plan comparison for the c-spine chordoma patient is presented in figure 5. Dose coverage
of the extended target, CTV or CTD, was optimized under the constraints limiting the
mean dose to the spinal cord and the mean dose to the pharynx. The spinal cord was
located within the binary CTV delineated by radiation oncologists for the treatment
planning. When asked to draw the probability shells, the physician included the spinal
cord in the layer between the shells with probabilities r3=0.4 and r4=0.2, with the
latter matching the CTV. The pharynx was located immediately next to GTV and
11
Figure 4. IMRT plans for geometric phantom with anisotropic shells with optimized
dose coverage of the CTD under the constraint limiting the integral dose defined as
the mean dose within the phantom, Dmean. (a) Dmean =10 Gy; (b) Dmean = 5 Gy; (c)
Dmean = 2.95 Gy; (d) DVHs for the outermost layer (between green and cyan shells)
calculated from the three plans with Dmean =10 Gy (solid line), Dmean =5 Gy (dashed
line), and Dmean =2.95 Gy (dotted line).
intersected binary CTV. The shells were drawn to exclude the pharynx from the first two
inner layers and include it into the third layer, so it intersected shells with probabilities
r3 =0.4, r4 =0.2, and r5 =0. The proper coverage of the target was challenging since
the spinal cord was within the region assigned to receive the prescription dose. Sparing
the pharynx was less critical for the coverage requirement but still affected the anterior
periphery of the CTV. As shown in figure 5, both plans achieved the goal of sparing
the OARs, although the dose distribution within extended target was different. The
probabilistic CTD-based approach was superior to the conventional CTV approach in
covering regions marked with higher probabilities of finding tumor cells by shaping the
lower dose regions around both spinal cord and pharynx so that the dose fall-off followed
the decrease of tumor probability.
IMRT plans created for the glioblastoma patient are shown in figure 6. Panel (a)
presents a plan optimized to deliver the prescription dose of 60 Gy to the physician
defined CTV, while panels (b)-(d) present plans optimized to deliver the same dose to
the CTD with four probability layers. Dose coverage of the CTD was optimized using
three different levels of the mean brain dose. The constraints limiting the maximal dose
to the brainstem (60 Gy) and optic chiasm (54 Gy) were used for all plan optimizations.
With the mean brain dose of 37 Gy, the prescription dose conforms to the CTV contour
12
Figure 5. IMRT plans for the c-spine patient with optimized dose coverage of (a)
CTV (green shell), and (b) CTD with five probability layers. The plans are optimized
to deliver prescription dose to the CTV or CTD under constraints limiting the mean
dose to the spinal cord (blue) and pharynx (pink); (c) DVHs for layer 1 (between red
and orange shells shown by orange lines and layer 4 (between green and cyan shells)
shown by cyan lines calculated from the CTV plan (solid lines) and from the CTD
plan (dashed lines).
in the CTV plan (figure 6(a)) and to the shell that matches the CTV in the CTD plan
(figure 6(c)). With the brain Dmean=48 Gy the dose conforms to the outermost layer
(figure 6(b)). With the mean brain dose decreased to 31 Gy, the coverage extends only
to the shell closest to the GTV (figure 6(d)). The maximal dose constraints for the
optic chiasm and brainstem are satisfied for all plans, however, the distributions of the
dose within these structures are different for the binary CTV-based optimization and
for the layer-based optimization. Comparing DVHs in figure 6(e), it is clear that the
layer-based plan optimization results in steeper high dose gradient indicative of higher
dose in the proximity of the target.
3.3. Sensitivity analysis
We demonstrate the sensitivity of the dose distributions to the parameters of the CTD
formulation, and at the same time demonstrate that the CTV approach is in a certain
sense more sensitive to these decisions. Consider the target-OAR phantom of figure 1a.
Let x ∈ [0, 1] parametrize the distance from the GTV to the outer shell (r5 = 0). With
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Figure 6. IMRT plans for the glioblastoma patient. The plans are optimized to
deliver prescription dose to the CTV (a), and to the CTD with four layers (b-d) under
the constraint limiting the integral dose to the brain defined as the mean brain dose,
Dmean. (a) Dmean = 37 Gy; (b) Dmean = 48 Gy; (c) Dmean = 37 Gy; (d) Dmean = 31
Gy. The additional maximal dose constraint limits the dose to the brainstem (blue)
and optic chiasm (pink); (e) DVHs for the CTV (green lines), optic chiasm (pink lines),
and brainstem (blue lines) calculated from the CTV plan (solid lines) and from the
CTD plan with the same mean brain dose (panel (c)) (dashed lines).
that parametrization our nominal formulation for the decreasing shell probabilities is
given by r(x) = 0.8(1− x). Using the rule that the CTV boundary is where r(x) = 0.2
we have that location as x = 0.75. Now we consider a perturbed plan where the
system (physician or image-based auto-contouring algorithm) determines that the shell
14
Figure 7. Sensitivity analysis. The left column shows the sensitivity of the CTV-
based plan, which results from redefining the CTV contour consistent with how the
shell probabilities were altered for the CTD-based sensitivity demonstration. (a) is the
original CTV plan, (b) is the revised CTV plan arising from the CTV definition being
moved inward one shell, and (c) is the dose difference between these two plans. (d) is
the original CTD plan, (e) is the perturbed CTD plan, and (f) is the dose difference
map.
probabilities decrease faster. In particular we assume r(x) = 0.8(1 − x)2. Note this
does not alter the shell geometry, just the probabilities. Using this formula and solving
for the x location where r(x) = 0.2 places the CTV contour at x = 0.5, i.e. it moves
the CTV definition exactly one shell inward. We can now produce two plans, the
revised CTV plan and the revised CTD plan. For the CTD plan, we translate the new
rh probabilities into voxel level probabilities, using equation 3 and scaling by 100, as
before. This yields p = [0.85, 0.18, 0.055, 0.012] (in contrast with the nominal values of
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[0.58, 0.2, 0.09, 0.05]). These plans are compared in figure 7. The left column are the
CTV-based plans, and the right column are the CTD-based plans. The first row are the
original plans, re-displayed here for convenience. The second row shows the new plans
that arise from the perturbed rh values, and the final row shows the dose differences
(new plan minus original plan). Visual inspection of the plans, as quantified in the dose
difference maps, shows that the CTD plans are more similar to each other than the
CTV plans, in general and in particular within the target and OAR structures.
4. Discussion
We put forward a conceptual framework to deal with uncertainties in defining the clinical
target volume by defining it as a continuous probability distribution, CTD. The CTD
can be implemented in a straight-forward way in a commercial treatment planning
system, as we have shown. The concept has a number of advantages. Some of them
were demonstrated in this proof-of-principle article, while others are intuitive but have
not directly been proven.
The CTD allows the treatment planner to find the most suitable expansion of the
high dose region beyond the visible GTV. Specifically, the tradeoff between covering
areas that have a lower probability of being tumorous, and delivering higher doses to
the surrounding healthy organs, can be explored interactively by “navigating” (Mu¨ller
et al., 2017) between different options, as shown in figure 6(b)-(d). This is an advantage
over conventional planning approaches, which start with the CTV definition and do
not permit easy modification of the CTV later during the treatment planning process.
Drawing the CTV, the physicians often anticipate the tradeoff between target coverage
and sparing of critical organs, which may not reflect the natural physical dose tradeoff.
Drawing the target too tight compromises the probability of controlling the tumor,
whereas including too generous margins may unnecessarily compromise the function of
the surrounding healthy organs. In the CTD case, although the prescription dose still
has a binary distribution with a sharp boundary within the CTD, continuous control of
the objective function via the CTD will allow the physicians to make a choice in setting
the dose distribution to spare the OARs while covering the microscopic disease.
The CTD approach can yield better dose distributions. If a certain fraction of the
target needs to be excluded from receiving the therapeutic dose level in order to spare
neighbouring critical structures, the optimization algorithm can redistribute the dose
such that it affects primarily the parts of the CTD with lower probabilities of containing
tumor cells, see figure 3 and figure 7. In other regions where there is no competing OAR
nearby, the optimizer will deliver the full prescribed dose even in those voxels with small
probabilities of being tumorous. This can be seen in all our examples by looking at the
outer CTD layers.
As far as the optimization formulation using probabilities is concerned, we use a first
order approximation (neglecting the βD2 term of the linear-quadratic formulation) as
well as some algebraic simplifications to arrive at the clean voxel probability weighted
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sum formulation (5), but other derivations should be examined in future studies. In
other future studies one could examine if a similar voxel-weighted probability approach
could be applied in a meaningful way to deal with uncertainties in defining normal
tissues.
One expected advantage of the CTD approach is that it will reduce the inter-
physician variability of drawing the CTV. We haven’t proven this hypothesis but for
the following reason it is likely to be true: Consider a case where two physician are
unsure whether a certain sub-volume should be included in the clinical target volume
or not. Both think the probability that the sub-volume is tumor is of the order of 10%.
Based on that, physician A decides to include it in the CTV, physician B does not.
The difference between their CTVs is 100% in that region, whereas the probabilities, ie,
the CTDs, are approximately the same. This fundamental difference–the all-or-nothing
nature of CTV-based planning versus the smoothness of the CTD-based approach–is
also highlighted in the sensitivity analysis we performed.
We have not addressed the question of how to create the CTD. A few options
are mentioned in the introduction. The most realistic short term approach is to have
physicians enter an error margin while they draw the CTV. The error margin is then
converted to our probability shells as mentioned in section 2.1. Another option is for
them to mark areas of uncertain CTV by directly entering a probability level. The
ultimate long-term goal is to move away from subjective levels of uncertainty to objective
measures of the probability of finding tumor in a voxel. This gold standard can be
achieved through pathological studies (van Loon et al., 2012, Siedschlag et al., 2011,
Akiyama et al., 2018).
An open question is also how to evaluate the resulting dose distributions, given the
uncertain nature of the CTD. In this paper we provided dose volume histograms (DVH)
for different shells around the GTV, which is a workable approach. Another option is
to create a DVH which plots the expected volume for each dose bin. Here the volume of
a voxel with a tumor probability of p < 100% is weighted with that factor p.
We restricted ourselves to the consideration of uncertainties in the CTV definition
without considering setup errors, motion, and other sources of spatial uncertainty.
Traditionally, those errors are taken into account by adding another margin to the
CTV, leading to the “planning target volume” (PTV). In the case of the CTD it is
not obvious how to add the PTV margin. However, a more advanced recent approach
to handle spatial uncertainties is through robust, probabilistic, and 4D optimization
(Fredriksson, 2012, Chen et al., 2012, Trofimov et al., 2005, Witte et al., 2018), which
can be applied in a straight-forward manner to the CTD-based plan.
To align our approach with common clinical practice, we use a dose based objective
function with a fixed prescription dose in our problem formulation, equation (5). In
particular, we are not using a “dose painting” approach (Ling et al., 2000). Like the
dependence of the prescription dose on the tumor cell density, the dependence on the
tumor probability p is a small logarithmic dependence (Webb and Nahum, 1993). This
is due to the exponential nature of the cell kill. We wish to point out an important
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difference between variable tumor cell density and variable tumor probability though.
Consider a sub-volume of the target where the tumor cell density is only 5% of the
density in the rest of the tumor. This sub-volume requires approximately the same dose
as the rest of target. In particular, if we drop the dose to zero in that sub-volume,
the TCP drops to zero as well. On the other hand, if the tumor probability of the
sub-volume is 5% (i.e., only 5% of the patients have tumor in that sub-volume), then
we can drop the dose to zero and the TCP will only drop by approximately 5%.
5. Conclusions
Moving away from the binary CTV concept towards the more natural and more
descriptive CTD concept represents a sizable break from tradition. However, given
the potential dosimetric improvements and expected increase in delineation consistency
across physicians, we believe that the concept is worth exploring further. Although
similar to dose-painting approaches, the CTD concept uses voxel level probabilities–
together with treatment plan constraints and objectives – to determine how each CTD
voxel is dosed. It remains to be seen which approach makes more sense in a clinical
setting.
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